Grifols, S.A. (GRFS)
Healthcare
- Fundamental
- 3
- Sentiment
- 4
- Technical
- 2
Do Nothing: avgDollarVolume20 ~$3.04M is below the $5M liquidity floor; no bullish setup qualifies either — no breakout stop exists (price below SMA20/50/200 with negative MACD) and a pullback limit would be countertrend (price < SMA50 with MACD < 0).
Company overview
Grifols, S.A., founded in 1940 and based in Barcelona, Spain, develops, manufactures, and distributes therapeutic products primarily derived from human plasma. The company operates through several divisions, including Bioscience, Hospital, Diagnostic, and Bio Supplies, serving healthcare organizations worldwide. Grifols' products address conditions such as hemophilia, immune deficiencies, and infectious diseases.
Fundamental
fairProfitability is improving, but high leverage and plasma-supply risks persist.
Mixed: improving profitability and refinancing reduced near-term maturity pressure, but leverage remains elevated (~4.2x net debt/EBITDA) and the business is exposed to plasma-supply and regulatory risks; valuation and DCF metrics were unavailable in this run.
Sentiment
goodPositive media coverage and recent clinical milestones support a constructive narrative.
Short-term tone is constructive on an Aug 10 Phase 3 SPARTA milestone (announced) and a positively framed Jul 28 earnings/call cycle; baseline media sentiment was also bullish, implying a roughly flat (still positive) sentiment backdrop. No regulator-confirmed investigations surfaced in the last 90d, though court-record discovery was partially limited by a CAPTCHA warning.
Technical
weakPrice is below key moving averages with no momentum turn, indicating a weak bearish trend.
Weak bearish drift, not a tradable long. Price 7.36 sits below every key moving average (SMA20 7.68, SMA50 7.74, SMA200 8.23, EMA9 7.47, EMA21 7.61) in a lower-highs/lower-lows sequence from ~8.05 on 08-10. Momentum is negative: MACD line -0.13 below signal -0.08 with a -0.05 histogram, RSI 37.32, Williams %R -90 (oversold-tagged but no turn). ADX 14.93 shows no trend strength — a slow grind, not a climax. Score 2 = mostly weak bearish with bounce-only potential. Independently, the liquidity floor fails (avgDollarVolume20 ~$3.04M < $5M), so the action is Do Nothing even though the technical read itself loaded cleanly.
You’re looking at 2026-09-21 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.